Skip to main content

Lopinavir / ritonavir Side Effects

Medically reviewed by Last updated on Feb 18, 2024.

Applies to lopinavir / ritonavir: oral solution, oral tablet.

Serious side effects

Along with its needed effects, lopinavir / ritonavir may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.

Check with your doctor immediately if any of the following side effects occur while taking lopinavir / ritonavir:

Less common

Incidence not known

Get emergency help immediately if any of the following symptoms of overdose occur while taking lopinavir / ritonavir:

Symptoms of overdose

Other side effects

Some side effects of lopinavir / ritonavir may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.

Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:

Less common

Incidence not known

For Healthcare Professionals

Applies to lopinavir / ritonavir: oral capsule, oral liquid, oral tablet.


In clinical studies, this drug was used with nucleoside reverse transcriptase inhibitors with or without efavirenz or nevirapine. The most common side effects were diarrhea, nausea, vomiting, hypertriglyceridemia, and hypercholesterolemia. Diarrhea, nausea, and vomiting occurred more often at the start of therapy while hypertriglyceridemia and hypercholesterolemia generally occurred later. Diarrhea was reported more often when this drug was used once a day than when it was used twice a day.[Ref]


Very common (10% or more): Increased total cholesterol (up to 39%), increased triglycerides (up to 36%)

Common (1% to 10%): Fatigue, asthenia, pain, decreased weight, pyrexia, chills, decreased inorganic phosphorus

Uncommon (0.1% to 1%): Increased weight

Frequency not reported: Generalized pain, back and abdomen enlargement, chest pain, cyst, edema, peripheral edema, face edema, influenza syndrome, hypertrophy, malaise, drug interaction, increased drug level, bacterial infection, viral infection, otitis media, breast enlargement

Antiretroviral therapy:

-Frequency not reported: Increased weight, increased blood lipid levels[Ref]

Increased total cholesterol (greater than 300 mg/dL) and triglycerides (greater than 750 mg/dL) have been reported in up to 39% and up to 36% of patients, respectively. Decreased inorganic phosphorus (less than 1.5 mg/dL) has been reported in up to 2% of patients.[Ref]


Very common (10% or more): Increased GGT (up to 29%), increased ALT (up to 11%)

Common (1% to 10%): Increased AST, hepatitis (including increased AST, ALT, GGT), increased total bilirubin

Uncommon (0.1% to 1%): Hepatomegaly, cholangitis, hepatic steatosis, hyperbilirubinemia, jaundice

Frequency not reported: Fatty liver deposit, cytolytic hepatitis, liver tenderness, hepatic failure, cholecystitis, hepatic dysfunction

Postmarketing reports: Jaundice, hepatitis[Ref]

Increased GGT (greater than 300 units/L), ALT (greater than 215 units/L), AST (greater than 180 units/L), and total bilirubin (greater than 3.48 mg/dL) have been reported in up to 29%, up to 11%, up to 10%, and 1% of patients, respectively.

Patients with underlying hepatitis B or C or marked elevations in transaminases before initiation of therapy may be at an increased risk for developing further transaminase elevations or liver decompensation. There have been reports of hepatic dysfunction with some cases leading to death. A causal relationship with this drug has not been proven since these cases have generally occurred in patients with advanced HIV who also had underlying chronic hepatitis or cirrhosis and were taking multiple concomitant medications.[Ref]


Very common (10% or more): Diarrhea (up to 28%), nausea (up to 16%)

Common (1% to 10%): Increased amylase, vomiting, abdominal pain, upper abdominal pain, lower abdominal pain, increased lipase, gastroenteritis and colitis, dyspepsia, pancreatitis, gastroesophageal reflux disease, hemorrhoids, flatulence, abdominal distention, abnormal feces, constipation, dysphagia

Uncommon (0.1% to 1%): Stomatitis and oral ulcers, duodenitis, gastritis, gastrointestinal hemorrhage (including rectal hemorrhage), dry mouth, gastrointestinal ulcer, fecal incontinence

Frequency not reported: Abdominal discomfort, enteritis, enterocolitis, eructation, esophagitis, gastric disorder, gastric ulcer, hemorrhagic enterocolitis, mouth ulceration, periodontitis, sialadenitis, stomach discomfort, ulcerative stomatitis[Ref]

Increased amylase (greater than 2 times the upper limit of normal [2 x ULN]) and lipase (greater than 2 x ULN) were reported in up to 8% and up to 5% of patients, respectively.

Pancreatitis, including fatalities, has occurred in patients receiving this drug, including those who developed hypertriglyceridemia. Although a causal relationship has not been established, marked triglyceride elevation is a risk factor for the development of pancreatitis.[Ref]


Very common (10% or more): Upper respiratory tract infection (up to 13.9%)

Common (1% to 10%): Lower respiratory tract infection, bronchitis

Frequency not reported: Asthma, bronchopneumonia, dyspnea, pulmonary edema, pharyngitis, rhinitis, increased cough, sinusitis, influenza[Ref]


Increased glucose (greater than 250 mg/dL) and uric acid (greater than 12 mg/dL) have each been reported in up to 5% of patients.

Episodes of hyperglycemia, new onset diabetes mellitus, and exacerbation of preexisting diabetes mellitus have been reported during postmarketing studies in HIV-infected patients receiving protease inhibitors. In some cases, diabetic ketoacidosis has occurred. No causal relationship has been established.[Ref]

Common (1% to 10%): Hypercholesterolemia, hypertriglyceridemia, increased glucose, increased uric acid, decreased appetite, blood glucose disorders (including diabetes mellitus), anorexia

Uncommon (0.1% to 1%): Lactic acidosis, increased appetite

Frequency not reported: Avitaminosis, hypovitaminosis, dehydration, dyslipidemia, hyperamylasemia, hyperlipasemia, decreased glucose tolerance, lipomatosis, obesity, hyperglycemia, new onset diabetes mellitus, exacerbation of preexisting diabetes mellitus, ketoacidosis, insulin resistance, hyperlactatemia

Postmarketing reports: Redistribution/accumulation of body fat (including central obesity, dorsocervical fat enlargement, peripheral wasting, facial wasting, breast enlargement, "cushingoid appearance")

Combination antiretroviral therapy:

-Frequency not reported: Redistribution of body fat (fat loss or fat gain)

Antiretroviral therapy:

-Frequency not reported: Redistribution/accumulation of body fat, increased glucose levels[Ref]


Common (1% to 10%): Musculoskeletal pain (including arthralgia, back pain), increased creatine phosphokinase, myalgia, muscle disorders (such as weakness, spasms)

Uncommon (0.1% to 1%): Rhabdomyolysis, osteonecrosis

Frequency not reported: Arthropathy, arthrosis, muscular weakness, joint disorder, osteoarthritis, extremity pain, myasthenia, myositis, perineal abscess[Ref]

Increased creatine phosphokinase (greater than 4 x ULN) was reported in up to 5% of patients.[Ref]

Nervous system

Common (1% to 10%): Headache (including migraine), neuropathy (including peripheral neuropathy), dizziness, paresthesia

Uncommon (0.1% to 1%): Ageusia, convulsion, vertigo, tremor, cerebrovascular accident/event, tinnitus, dysgeusia

Frequency not reported: Amnesia, ataxia, balance disorder, abnormal coordination, cerebral infarction, dyskinesia, encephalopathy, facial paralysis/palsy, hypertonia, peripheral neuritis, somnolence, hyperacusis, extrapyramidal disorder[Ref]


Common (1% to 10%): Decreased neutrophils, anemia, decreased hemoglobin, leukopenia, neutropenia, lymphadenopathy

Rare (less than 0.1%): Hemolytic anemia, spontaneous bleeding in hemophiliacs

Frequency not reported: Splenomegaly[Ref]

Decreased neutrophils (less than 0.75 x 10[9]/L) and hemoglobin (less than 8 g/dL) have been reported in up to 5% and up to 2% of patients, respectively.[Ref]


Common (1% to 10%): Anxiety, insomnia, decreased libido, depression

Uncommon (0.1% to 1%): Abnormal dreams

Frequency not reported: Affect lability, agitation, apathy, confusional state, disorientation, mood swings, nervousness, abnormal thinking[Ref]


Common (1% to 10%): Rash (including maculopapular rash), skin infections (including cellulitis, folliculitis, furuncle), acquired lipodystrophy (including facial wasting), dermatitis/rash (including eczema, seborrheic dermatitis), night sweats, pruritus

Uncommon (0.1% to 1%): Alopecia, capillaritis, vasculitis

Rare (0.01% to 0.1%): Stevens-Johnson syndrome, erythema multiforme

Frequency not reported: Acne, dry skin, acneiform dermatitis, allergic dermatitis, exfoliative dermatitis, idiopathic capillaritis, generalized rash, nail disorder, seborrhea, benign skin neoplasm, skin discoloration, skin hypertrophy, skin ulcer, skin striae, swelling face, hyperhidrosis, acute generalized exanthematous pustulosis, furunculosis

Postmarketing reports: Toxic epidermal necrolysis, Stevens-Johnson syndrome, erythema multiforme[Ref]


Common (1% to 10%): Decreased calculated CrCl, renal failure

Uncommon (0.1% to 1%): Nephritis

Frequency not reported: Nephrolithiasis, renal disorder

Postmarketing reports: Nephrolithiasis[Ref]

Decreased calculated CrCl (less than 50 mL/min) was reported in up to 3% of patients.[Ref]


Common (1% to 10%): Hypersensitivity (including urticaria, angioedema)

Frequency not reported: Drug hypersensitivity, severe skin and mucous hypersensitivity reaction with transient multiorgan failure[Ref]


Common (1% to 10%): Hypertension, vasodilatation

Uncommon (0.1% to 1%): Deep vein thrombosis, atherosclerosis (such as myocardial infarction), atrioventricular (AV) block, tricuspid valve incompetence

Frequency not reported: Distended veins, angina pectoris, atrial fibrillation, chest pain, palpitation, orthostatic hypotension, thrombophlebitis, varicose vein, vasculitis, sinus arrest, bradycardia-tachycardia syndrome

Postmarketing reports: Bradyarrhythmias, first-degree AV block, second-degree AV block, third-degree AV block, QTc interval prolongation, torsades de pointes[Ref]


Common (1% to 10%): Erectile dysfunction, menstrual disorders, amenorrhea, menorrhagia

Uncommon (0.1% to 1%): Hematuria

Frequency not reported: Ejaculation disorder, impotence, abnormal urine odor, urine abnormality[Ref]


Common (1% to 10%): Hypogonadism

Frequency not reported: Cushing's syndrome, hypothyroidism, gynecomastia[Ref]


Uncommon (0.1% to 1%): Visual impairment

Frequency not reported: Visual disturbance, eye disorder[Ref]


Uncommon (0.1% to 1%): Immune reconstitution syndrome/immune reconstitution inflammatory syndrome

Frequency not reported: Autoimmune disorders in the setting of immune reconstitution (e.g., Graves' disease, polymyositis, Guillain-Barre syndrome, autoimmune hepatitis)


Frequency not reported: Neoplasm, lipoma


1. (2001) "Product Information. Kaletra (lopinavir-ritonavir)." Abbott Pharmaceutical

2. Hicks C, King MS, Gulick RM, et al. (2004) "Long-term safety and durable antiretroviral activity of lopinavir / ritonavir in treatment-naive patients: 4 year follow-up study." AIDS, 18, p. 775-779

3. Guest JL, Ruffin C, Tschampa JM, DeSilva KE, Rimland D (2004) "Differences in rates of diarrhea in patients with human immunodeficiency virus receiving lopinavir-ritonavir or nelfinavir." Pharmacotherapy, 24, p. 727-35

4. Cerner Multum, Inc. "UK Summary of Product Characteristics."

5. Borras-Blasco J, Belda A, Rosique-Robles D, Castera E, Abad J, Amoros-Quiles I (2007) "Hair loss induced by lopinavir-ritonavir." Pharmacotherapy, 27, p. 1215-8

6. Leon A, Martinez E, Sarasa M, et al. (2007) "Impact of steady-state lopinavir plasma levels on plasma lipids and body composition after 24 weeks of lopinavir / ritonavir-containing therapy free of thymidine analogues." J Antimicrob Chemother

7. Warnke D, Barreto J, Temesgen Z (2007) "Antiretroviral drugs." J Clin Pharmacol, 47, p. 1570-9

8. Cerner Multum, Inc. "Australian Product Information."

9. Rabaud C, Burty C, Grandidier M, et al. (2005) "Tolerability of postexposure prophylaxis with the combination of zidovudine-lamivudine and lopinavir-ritonavir for HIV infection." Clin Infect Dis, 40, p. 303-5

10. Johnson M, Grinsztejn B, Rodriguez C, et al. (2006) "96-week comparison of once-daily atazanavir/ritonavir and twice-daily lopinavir / ritonavir in patients with multiple virologic failures." AIDS, 20, p. 711-718

11. Cameron DW, Becker S, King MS, et al. (2007) "Exploratory study comparing the metabolic toxicities of a lopinavir / ritonavir plus saquinavir dual protease inhibitor regimen versus a lopinavir / ritonavir plus zidovudine/lamivudine nucleoside regimen." J Antimicrob Chemother, 59, p. 957-63

12. (2009) "Drugs for HIV infection." Treat Guidel Med Lett, 7, p. 11-22

13. Bongiovanni M, Bini T, Tordato F, et al. (2003) "Immunovirological outcomes in 70 HIV-1-infected patients who switched to lopinavir / ritonavir after failing at least one protease inhibitor-containing regimen: a retrospective cohort study." J Antimicrob Chemother, 51, p. 171-4

14. Martinez E, Domingo P, Galindo MJ, et al. (2004) "Risk of metabolic abnormalities in patients infected with HIV receiving antiretroviral therapy that contains lopinavir-ritonavir." Clin Infect Dis, 38, p. 1017-23

15. Doco-Lecompte T, Garrec A, Thomas L, Trechot P, May T, Rabaud C (2004) "Lopinavir-ritonavir (Kaletra) and lithiasis: seven cases." AIDS, 18, p. 705-6

16. Canta F, Marrone R, Bonora S, et al. (2005) "Pharmacokinetics and hepatotoxicity of lopinavir / ritonavir in non-cirrhotic HIV and hepatitis C virus (HCV) co-infected patients." J Antimicrob Chemother

17. Johnson M, Grinsztejn B, Rodriguez C, et al. (2005) "Atazanavir plus ritonavir or saquinavir, and lopinavir / ritonavir in patients experiencing multiple virological failures." AIDS, 19, p. 685-94

18. Manfredi R, Sabbatani S (2006) "Serious, multi-organ hypersensitivity to lopinavir alone, involving cutaneous-mucous rash, and myeloid, liver, and kidney function." AIDS, 20, p. 2399-2400

19. Soriano V, Puoti M, Sulkowski M, et al. (2007) "Care of patients coinfected with HIV and hepatitis C virus: 2007 updated recommendations from the HCV-HIV International Panel." AIDS, 21, p. 1073-89

20. Voigt E, Wasmuth JC, Vogel M, et al. (2004) "Safety, Efficacy and Development of Resistance under the New Protease Inhibitor Lopinavir/Ritonavir: 48-Week Results." Infection, 32, p. 82-8

21. Hammer SM, Saag MS, Schechter M, et al. (2006) "Treatment for adult HIV infection: 2006 recommendations of the International AIDS Society-USA panel." JAMA, 296, p. 827-43

22. Brennan-Benson P, Pakianathan M, Rice P, et al. (2006) "Enfurvitide prevents vertical transmission of multidrug-resistant HIV-1 in pregnancy but does not cross the placenta." AIDS, 20, p. 297-9

23. Molto J, Santos JR, Negredo E, Miranda C, Videla S, Clotet B (2007) "Lopinavir / ritonavir monotherapy as a simplification strategy in routine clinical practice." J Antimicrob Chemother, 60, p. 436-9

24. Roberts DM, Ray JE, Buckley NA (2008) "Mild clinical toxicity and dose-dependent pharmacokinetics following acute lopinavir / ritonavir poisoning in a HIV-positive patient." AIDS, 22, p. 792-3

25. Borras-Blasco J, Navarro-Ruiz A, Borras C, Castera E (2008) "Adverse cutaneous reactions associated with the newest antiretroviral drugs in patients with human immunodeficiency virus infection." J Antimicrob Chemother, 62, p. 879-88

26. Badiou S, De Boever CM, Dupuy AM, Baillat V, Cristol JP, Reynes J (2003) "Small dense LDL and atherogenic lipid profile in HIV-positive adults: influence of lopinavir / ritonavir-containing regimen." AIDS, 17, p. 772-4

27. Bergersen BM (2006) "Cardiovascular Risk in Patients with HIV Infection : Impact of Antiretroviral Therapy." Drugs, 66, p. 1971-87

28. Yazdanpanah Y, Viget N, Cheret A, et al. (2003) "Increased bleeding in HIV-positive haemophiliac patients treated with lopinavir-ritonavir." AIDS, 17, p. 2397-9

29. Ghosn J, Duvivier C, Tubiana R, Katlama C, Caumes E (2005) "Acute generalized exanthematous pustulosis induced by HIV postexposure prophylaxis with lopinavir-ritonavir." Clin Infect Dis, 41, p. 1360-1

30. Yotsumoto M, Kitano K, Saito H (2005) "Bradycardia-tachycardia syndrome induced by lopinavir-ritonavir in a patient with AIDS." AIDS, 19, p. 1547-8

31. Worm SW, Sabin C, Weber R, et al. (2009) "Risk of myocardial infarction in patients with HIV infection exposed to specific individual antiretroviral drugs from the 3 major drug classes: The Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) Study." J Infect Dis, 201, p. 318-30

32. Calza L, Manfredi R, Verucchi G (2010) "Myocardial infarction risk in HIV-infected patients: epidemiology, pathogenesis, and clinical management." AIDS, 24, p. 789-802

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Some side effects may not be reported. You may report them to the FDA.